ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013.The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively
It’s new cannabinoid
IUPAC name: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
Purity: 99,7% min
Appearance: white powder
The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.